Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
Benchmark Downgrades Emergent BioSolutions to Hold
Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
Related Posts
ADM Exceeds 2M Regenerative Agriculture Acre Goal For 2023, Targeting 3.5M Regenerative Acres In 2024, Increases 2025 Goal To 5M Acres
Launch of regenerative agriculture initiatives in Europe, Latin America accelerate global progress as company works toward 3.5 million acres in 2024ADM (NYSE:ADM) announced today that its global regenerative agriculture
Accenture And Workday Expand Partnership To Help Organizations Accelerate Finance Transformation
Co-innovation helps companies like Salesforce reimagine its financial processes globally
Accenture (NYSE:ACN) and Workday (NASDAQ:WDAY) are expanding their partnership to help organizations reinvent their